Skip to main content
PMC home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2009 Jul;6(3):598–603. doi: 10.1016/j.nurt.2009.04.012

Current management of metastatic brain disease

Tulika Ranjan 1, Lauren E Abrey 1,✉
PMCID: PMC5084194  PMID: 19560748

Summary

Brain metastases are the most common intracranial tumor in adults. The incidence of metastases is thought to be rising due to better detection and treatment of systemic malignancy. More widespread use and improved quality of MRI may lead to early detection of brain metastases. Available evidence suggests that survival is longer and quality of life improved if brain metastases are treated aggressively. This article reviews current therapeutic management used for brain metastases. To select the appropriate therapy, the physician must consider the extent of the systemic disease, primary histology, and patient age and performance status, as well as the number, size, and location of the brain metastases. Available treatment options include whole-brain radiotherapy (WBRT), stereotactic radiosurgery (SRS), surgery, and chemotherapy. Multidisciplinary approaches such as the combination of WBRT with SRS or surgery have shown superior results in terms of survival time, neurocognitive function, and quality of life. The utility and optimal use of chemotherapy and radiosensitizing agents is less clear. It is hoped that further advances and multidisciplinary approaches currently under study will result in improved patient outcomes.

Key Words: Brain metastases, brain metastasis chemotherapy, brain metastasis radiotherapy, metastatic brain tumor, brain neoplasm

References

  • 1.Patchell R. Brain metastases. Handb Neurol. 1997;25:135–135. [Google Scholar]
  • 2.Posner JB. Management of brain metastases. Rev Neurol (Paris) 1992;148:477–487. [PubMed] [Google Scholar]
  • 3.Sawaya R, Bindal RK. Metastatic brain tumors. In: Kaye AH, Laws ER, editors. Brain tumors. 2nd ed. Edinburgh: Churchill Livingstone; 2001. pp. 999–1026. [Google Scholar]
  • 4.Graus F, Walker RW, Allen JC. Brain metastases in children. J Pediatr. 1983;103:558–561. doi: 10.1016/S0022-3476(83)80583-6. [DOI] [PubMed] [Google Scholar]
  • 5.Wen PY, Loeffler JS. Management of brain metastases. Oncology. 1999;13:941–954. [PubMed] [Google Scholar]
  • 6.Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin N Am. 1996;7:337–344. [PubMed] [Google Scholar]
  • 7.Raizer JJ, Abrey LE, editors. Brain metastases. New York: Springer; 2007. [Google Scholar]
  • 8.Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res. 2007;13:1648–1655. doi: 10.1158/1078-0432.CCR-06-2478. [DOI] [PubMed] [Google Scholar]
  • 9.Stemmler J, Schmitt M, Willems A, et al. Brain metastases in HER-2 overexpressing metastatic breast cancer: comparative analysis of trastuzumab levels in serum and cerebrospinal fluid. J Clin Oncol. 2006;24:64s–64s. doi: 10.1200/JCO.2005.02.5825. [DOI] [Google Scholar]
  • 10.Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol. 2000;18:2349–2351. doi: 10.1200/JCO.2000.18.11.2349. [DOI] [PubMed] [Google Scholar]
  • 11.Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS. Scizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc. 2004;79:1489–1494. doi: 10.4065/79.12.1489. [DOI] [PubMed] [Google Scholar]
  • 12.Shehata MK, Young B, Reid B, et al. Stereotactic radiosurgery of 468 brain metastases ≤2 cm: implications for SRS dose and whole brain radiation therapy. Int J Radiat Oncol Biol Phys. 2004;59:87–93. doi: 10.1016/j.ijrobp.2003.10.009. [DOI] [PubMed] [Google Scholar]
  • 13.Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280:1485–1489. doi: 10.1001/jama.280.17.1485. [DOI] [PubMed] [Google Scholar]
  • 14.Caimcross JG, Kim JH, Posner JB. Radiation therapy for brain metastases. Ann Neurol. 1980;7:529–541. doi: 10.1002/ana.410070606. [DOI] [PubMed] [Google Scholar]
  • 15.Byrne TN, Cascino TL, Posner JB. Brain metastasis from melanoma. J Neurooncol. 1983;1:313–317. doi: 10.1007/BF00165714. [DOI] [PubMed] [Google Scholar]
  • 16.Cascino TL, Leavengood JM, Kemeny N, Posner JB. Brain metastases from colon cancer. J Neurooncol. 1983;1:203–209. doi: 10.1007/BF00165604. [DOI] [PubMed] [Google Scholar]
  • 17.Gay PC, Litchy WJ, Cascino TL. Brain metastasis in hypernephroma. J Neurooncol. 1987;5:51–56. doi: 10.1007/BF00162765. [DOI] [PubMed] [Google Scholar]
  • 18.Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol. 2007;25:1260–1266. doi: 10.1200/JCO.2006.09.2536. [DOI] [PubMed] [Google Scholar]
  • 19.Rades D, Haatanen T, Schild SE. Dose escalation beyond 30 grays in 10 fractions for patients with multiple brain metastases. Cancer. 2007;110:1345–1350. doi: 10.1002/cncr.22906. [DOI] [PubMed] [Google Scholar]
  • 20.Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745–751. doi: 10.1016/S0360-3016(96)00619-0. [DOI] [PubMed] [Google Scholar]
  • 21.Kurtz JM, Gelber R, Brady LW, Carella RJ, Cooper JS, Radiation Therapy Oncology Group The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1981;7:891–895. doi: 10.1016/0360-3016(81)90005-5. [DOI] [PubMed] [Google Scholar]
  • 22.Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003;21:2529–2536. doi: 10.1200/JCO.2003.12.122. [DOI] [PubMed] [Google Scholar]
  • 23.Suh JH, Stea B, Nabid A, et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol. 2006;24:106–114. doi: 10.1200/JCO.2004.00.1768. [DOI] [PubMed] [Google Scholar]
  • 24.Cerchietti LC, Bonomi MR, Navigante AH, Castro MA, Cabalar ME, Roth BM. Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases. J Neurooncol. 2005;71:73–81. doi: 10.1007/s11060-004-9179-x. [DOI] [PubMed] [Google Scholar]
  • 25.Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: a novel radiation sensitizer. Cancer Res. 1992;52:3495–3497. [PubMed] [Google Scholar]
  • 26.DeAngelis LM, Currie VE, Kim JH, et al. The combined use of radiation therapy and lonidamine in the treatment of brain metastases. J Neurooncol. 1989;7:241–247. doi: 10.1007/BF00172917. [DOI] [PubMed] [Google Scholar]
  • 27.Eyre HJ, Ohlsen JD, Frank J, et al. Southwest Oncology Group Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain. A Southwest Oncology Group study. J Neurooncol. 1984;2:325–330. doi: 10.1007/BF00178115. [DOI] [PubMed] [Google Scholar]
  • 28.Komarnicky LT, Phillips TL, Martz K, Asbell S, Isaacson S, Urtasun R. A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916) Int J Radiat Oncol Biol Phys. 1991;20:53–58. doi: 10.1016/0360-3016(91)90137-S. [DOI] [PubMed] [Google Scholar]
  • 29.Phillips TL, Scott CB, Leibel SA, Rotman M, Weigensberg IJ. Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys. 1995;33:339–348. doi: 10.1016/0360-3016(95)00168-X. [DOI] [PubMed] [Google Scholar]
  • 30.Conill C, Berenguer J, Vargas M, et al. Incidence of radiation-induced leukoencephalopathy after whole brain radiotherapy in patients with brain metastases. Clin Transl Oncol. 2007;9:590–595. doi: 10.1007/s12094-007-0108-2. [DOI] [PubMed] [Google Scholar]
  • 31.DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989;39:789–796. doi: 10.1212/wnl.39.6.789. [DOI] [PubMed] [Google Scholar]
  • 32.Simonová G, Liscák R, Novotný J, Novotný J. Solitary brain metastases treated with the Leksell gamma knife: prognostic factors for patients. Radiother Oncol. 2000;57:207–213. doi: 10.1016/S0167-8140(00)00267-X. [DOI] [PubMed] [Google Scholar]
  • 33.Vogelbaum MA, Angelov L, Lee SY, Li L, Barnett GH, Suh JH. Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin. J Neurosurg. 2006;104:907–912. doi: 10.3171/jns.2006.104.6.907. [DOI] [PubMed] [Google Scholar]
  • 34.Varlotto JM, Flickinger JC, Niranjan A, Bhatnagar AK, Kondziolka D, Lunsford LD. Analysis of tumor control and toxicity in patients who have survived at least one year after radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys. 2003;57:452–464. doi: 10.1016/S0360-3016(03)00568-6. [DOI] [PubMed] [Google Scholar]
  • 35.Xu N, Shu H, Marcus R, Crocker IR. Radiation necrosis after stereotactic radiosurgery for metastatic brain disease. Int J Radiat Oncol Biol Phys. 2007;69:S163–S163. [Google Scholar]
  • 36.Müller-Riemenschneider F, Bockelbrink A, et al. Stereotactic radiosurgery for the treatment of brain metastases. Radiother Oncol. 2009;91:67–74. doi: 10.1016/j.radonc.2008.12.001. [DOI] [PubMed] [Google Scholar]
  • 37.Moser RP, Johnson ML. Surgical management of brain metastases: how aggressive should we be? Oncology. 1989;3:123–127. [PubMed] [Google Scholar]
  • 38.Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494–500. doi: 10.1056/NEJM199002223220802. [DOI] [PubMed] [Google Scholar]
  • 39.Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993;33:583–590. doi: 10.1002/ana.410330605. [DOI] [PubMed] [Google Scholar]
  • 40.Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer. 1996;78:1470–1476. doi: 10.1002/(SICI)1097-0142(19961001)78:7<1470::AID-CNCR14>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
  • 41.Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665–1672. doi: 10.1016/S0140-6736(04)16250-8. [DOI] [PubMed] [Google Scholar]
  • 42.Kondziolka D, Patel A, Lunsford LD, et al. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys. 1999;45:427–434. doi: 10.1016/s0360-3016(99)00198-4. [DOI] [PubMed] [Google Scholar]
  • 43.Huang K, Sneed PK, Kunwar S, et al. Surgical resection and permanent iodine-125 brachytherapy for brain metastases. J Neurooncol. 2009;91:83–93. doi: 10.1007/s11060-008-9686-2. [DOI] [PubMed] [Google Scholar]
  • 44.Ewend MG, Brem S, Gilbert M, et al. Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clin Cancer Res. 2007;13:3637–3641. doi: 10.1158/1078-0432.CCR-06-2095. [DOI] [PubMed] [Google Scholar]
  • 45.Cortot AB, Gerinière L, Robinet G, et al. Groupe Lyon-Saint-Etienne d’Oncologie Thoracique; Groupe Français de Pneumo-Cancérologie. Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study. Ann Oncol. 2006;17:1412–1417. doi: 10.1093/annonc/mdl146. [DOI] [PubMed] [Google Scholar]
  • 46.Wu C, Li YL, Wang ZM, Li Z, Zhang TX, Wei Z. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer. 2007;57:359–364. doi: 10.1016/j.lungcan.2007.03.011. [DOI] [PubMed] [Google Scholar]
  • 47.Chiu CH, Tsai CM, Chen YM, Chiang SC, Liou JL, Perng RP. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer. 2005;47:129–138. doi: 10.1016/j.lungcan.2004.05.014. [DOI] [PubMed] [Google Scholar]
  • 48.Bernardo G, Cuzzoni Q, Strada MR, et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study. Cancer Invest. 2002;20:293–302. doi: 10.1081/CNV-120001173. [DOI] [PubMed] [Google Scholar]
  • 49.Fujita A, Fukuoka S, Takabatake H, Tagaki S, Sekine K. Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology. 2000;59:291–295. doi: 10.1159/000012185. [DOI] [PubMed] [Google Scholar]
  • 50.Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer. 1986;58:832–839. doi: 10.1002/1097-0142(19860815)58:4<832::AID-CNCR2820580404>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  • 51.Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer. 1992;69:972–978. doi: 10.1002/1097-0142(19920215)69:4<972::AID-CNCR2820690423>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  • 52.Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non-small cell lung carcinoma, or malignant melanoma: a prospective study. Cancer. 1999;85:1599–1605. doi: 10.1002/(SICI)1097-0142(19990401)85:7<1599::AID-CNCR23>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
  • 53.Abrey LE, Olson JD, Raizer JJ, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol. 2001;53:259–265. doi: 10.1023/A:1012226718323. [DOI] [PubMed] [Google Scholar]
  • 54.Lassman AB, Abrey LE, Shah GD, et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol. 2006;78:255–260. doi: 10.1007/s11060-005-9044-6. [DOI] [PubMed] [Google Scholar]
  • 55.Ron IG, Sarid D, Ryvo L, et al. A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study. Melanoma Res. 2006;16:65–69. doi: 10.1097/01.cmr.0000183921.46031.93. [DOI] [PubMed] [Google Scholar]
  • 56.Atkins MB, Sosman JA, Agarwala S, et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer. 2008;113:2139–2145. doi: 10.1002/cncr.23805. [DOI] [PubMed] [Google Scholar]
  • 57.Bafaloukos D, Tsoutsos D, Fountzilas G, et al. The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. Melanoma Res. 2004;14:289–294. doi: 10.1097/01.cmr.0000136707.60108.ab. [DOI] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES